Merck & Company stock analysis
Merck & Company (1MRKX) Stock Price & Analysis
1MRKX Stock Chart & Stats
- Day’s Range
- EUR 130.96 - EUR 132.00
- 52-Week Range
- EUR 53.01 - EUR 165.00
- Previous Close
- EUR 130.84
- Volume
- N/A
- Average Volume (3M)
- 169
- Market Cap
- EUR 328.91B
- Enterprise Value
- EUR 404.16B
- Total Cash (Recent Filing)
- EUR 9.65B
- Total Debt (Recent Filing)
- EUR 53.78B
- Price to Earnings (P/E)
- 150.2
- Beta
- 0.21
- Next Earnings
- Feb 02, 2027 (Est.)
- EPS Estimate
- 1.58
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 2.23%
Bulls Say, Bears Say
Bulls Say
Diversified Product Growth
Revenue growth is supported by multiple therapeutic and animal-health franchises rather than a single product. Continued contributions from new products, oncology and animal health broaden the earnings base and provide durable commercial momentum over the next several quarters.
Pipeline Strength
Late-stage clinical and regulatory progress strengthens Merck’s ability to replenish growth as mature products age. Positive results across oncology, vaccines and pulmonary hypertension diversify future launch opportunities and improve the durability of the portfolio.
Strong Cash Generation
Substantial operating and free cash flow gives Merck capacity to fund research, launches, capital needs, dividends and business development internally. Strong cash conversion supports financial resilience even while recent free-cash-flow growth has moderated.
Bears Say
Patent And Generic Headwinds
Upcoming loss of exclusivity and generic competition create a clearly identified pressure on revenue and earnings. The expected impact on BRIDION, Januvia and Adempas raises the execution burden for newer launches and pipeline products to offset mature-product erosion.
Profitability Deterioration
Lower operating and net margins reduce earnings quality and make reported profit less predictable, even though gross product economics remain strong. Elevated costs, charges or other below-gross-profit pressures could constrain operating leverage while Merck invests for future growth.
Higher Leverage
Higher leverage reduces balance-sheet flexibility and leaves less capacity to absorb setbacks or pursue opportunities without additional financing. The concurrent decline in equity and return on equity signals weaker recent financial resilience than in 2024–2025.
Merck & Company News
Merck Stock (MRK) Rises 2% on $830 Million Keytruda Sales Beat, Q3 Forecasts, and Higher Full-Year Profit Outlook
Merck & Co ($MRK) shares rose 2.14% in Thursday premarket trading after the drugmaker beat third-quarter Wall Street estimates and raised its full-year adjusted profit forecast. Strong demand for its
1MRKX FAQ
What was Merck & Company’s price range in the past 12 months?
What is Merck & Company’s market cap?
When is Merck & Company’s upcoming earnings report date?
How were Merck & Company’s earnings last quarter?
Is Merck & Company overvalued?
Does Merck & Company pay dividends?
What is Merck & Company’s EPS estimate?
How many shares outstanding does Merck & Company have?
What happened to Merck & Company’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Merck & Company?
What is the TipRanks Smart Score and how is it calculated?
Merck & Company Stock Smart Score
Company Description
Merck & Company
Merck & Co., Inc. is a global healthcare leader with operations spanning two core divisions: Pharmaceuticals and Animal Health. The Pharmaceutical segment is dedicated to human health, offering a broad spectrum of medicinal products. These cover crucial therapeutic areas such as oncology, acute hospital care, immunology, neuroscience, virology, cardiovascular conditions, and diabetes. This division also develops vital preventive vaccines for pediatric, adolescent, and adult populations. Meanwhile, the Animal Health segment focuses on the research, development, manufacturing, and marketing of veterinary medications, vaccines, and comprehensive health management solutions for animals. This division further provides innovative digital products designed for animal identification, traceability, and continuous monitoring. Merck's extensive clientele encompasses drug wholesalers, pharmacies, hospitals, and government agencies. It also serves managed healthcare organizations, including health maintenance organizations (HMOs) and pharmacy benefit managers, as well as various other institutional clients. Additionally, the company supplies products to individual physicians and their distributors, veterinarians, and livestock producers. The organization actively engages in strategic collaborations with companies such as AstraZeneca PLC, Bayer AG, Eisai Co., Ltd., Ridgeback Biotherapeutics, and Gilead Sciences, Inc. These partnerships are specifically aimed at the joint development and commercialization of prolonged-acting therapies for HIV. Established in 1891, Merck & Co., Inc. maintains its corporate headquarters in Kenilworth, New Jersey.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert Davis
- Employees
- 74,000
- Website
- www.merck.com
- Address
- 126 East Lincoln Avenue, Rahway, NJ, 07065, US
Merck & Company (1MRKX) Earnings & Revenues
1MRKX Company Deck
1MRKX Earnings Call
Earnings Call SentimentPositive
The call was strongly positive, with solid third-quarter revenue growth, raised 2026 guidance, strong performance from KEYTRUDA, WELIREG, WINREVAIR, Gardasil, and animal health, and multiple favorable clinical and regulatory milestones. Management expressed increased confidence in the pipeline and long-term growth beyond the KEYTRUDA loss-of-exclusivity period. Offsetting concerns included 2027 generic and loss-of-exclusivity headwinds, moderating KEYTRUDA growth, lower adult vaccination utilization, modestly lower gross margin, higher operating expenses, the QLEX European injunctions, and withdrawal of the ifinatamab deruxtecan application. Highlights significantly outweighed the lowlights.
View all IT:1MRKX earnings summaries1MRKX Net sales Breakdown
- 89.43% Pharmaceutical
- 9.77% Animal Health
- 0.79% Other
1MRKX Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 14 | 5 | 3 |
| Technical Analysis | 4 | 5 | 1 |
| Moving Averages | 10 | 0 | 2 |
